U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06940661) titled 'Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis' on March 14.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of obinutuzumab to induce clinical and serological remission in patients with relapsing PR3-ANCA granulomatosis with polyangiitis.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Granulomatosis With Polyangiitis
Intervention:
DRUG: Obinutuzumab
Patient will receive 1000 milligrams intravenous (IV) infusion on week 0, week 2, week 24 and week 26.
Patients will receive the same standardized glucocorticoid taper...